Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Respiratory Medicine

Topics

Medicine

Pathology

Physiology

Internal Medicine

Immunology And Allergy

Show all topics

DOI

10.1016/s2213-2600(15)00042-9